BDLSF (Inoviq) Growth Rank: 2 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDLSF Inoviq Ltd BDLSF
20 GF Score
Price $0.12
GF Value $0.15
! 3 Warning Signs
View Full Analysis

What is Inoviq Growth Rank?

Inoviq BDLSF 20 Growth Rank is 2 as of Sep. 05, 2026. GuruFocus rates BDLSF with a GF Score™ of 20/100 and a GF Value™ of $0.15. The stock has 3 warning signs investors should review.

Inoviq has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

BDLSF vs TMO, DHR, NTRA: Growth Rank Comparison

For the Diagnostics & Research subindustry, Inoviq's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inoviq Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Growth Rank distribution charts can be found below:

* The bar in red indicates where Inoviq's Growth Rank falls into.


BDLSF
20GF Score
Inoviq Ltd BDLSF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Inoviq (BDLSF) has a Growth Rank of 2 as of Sep. 05, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Inoviq and its competitors.
Is Inoviq's Growth Rank too high?
Inoviq's current Growth Rank is 2. Overall, Inoviq has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Growth Rank compare to TMO and DHR?
Inoviq's Growth Rank of 2 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Inoviq and its competitors. Inoviq's current Growth Rank is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Inoviq (BDLSF) has a current Growth Rank of 2. The stock's GF Value™ is $0.15, compared to a current price of $0.12 — trading 20% below its estimated fair value. The current Growth Rank is 2. Inoviq's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Inoviq (BDLSF), the current Growth Rank is 2 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inoviq (BDLSF) Overvalued in 2026?

Based on GuruFocus' analysis, Inoviq stock appears to be undervalued. The current stock price of $0.12 is trading 20% below its estimated GF Value™ of $0.15.

Key valuation signals for BDLSF:

  • Growth Rank: 2
  • GF Value™: $0.15 vs. price of $0.12 (20% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the BDLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inoviq Business Description

Other Exchanges IIQ:Australia
Address 23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
20GF Score

Get the complete analysis for BDLSF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.15
GF Value